SOURCE: Predictive Technology Group, Inc.

February 16, 2016 13:39 ET

Predictive Technology Group, Inc. (PRED) Acquires Remaining Outstanding Stake in Predictive Therapeutics, LLC

SALT LAKE CITY, UT--(Marketwired - February 16, 2016) - Predictive Technology Group, Inc. (OTC PINK: PRED) announces that it acquired the remaining minority position in Predictive Therapeutics, LLC. In March 2015, the Company acquired a majority stake, 84% control, in what is now the Company's subsidiary, Predictive Therapeutics, LLC.

A 16% minority stake has been acquired, and the Company has full 100% control of its subsidiary, Predictive Therapeutics, LLC.

Brad Robinson, President, Predictive Technology Group, Inc. states, "Even though PRED controlled the subsidiary since March 2015, the acquisition of the remaining 16% gives us full control and provides ease for accounting purposes."

The website, www.predrx.com, contains information about PRED's subsidiary, Predictive Therapeutics, LLC's business of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases' onsets and progressions. PRED's subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-3090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Contact Information

  • CONTACT:
    Rich Kaiser
    YES INTERNATIONAL
    757-306-6090